P2OD34 Stock Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.91 |
| 52 Week High | US$53.88 |
| 52 Week Low | US$27.91 |
| Beta | 1 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -48.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| P2OD34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -1.0% |
| 1Y | -48.2% | -5.0% | 13.1% |
Return vs Industry: P2OD34 underperformed the BR Medical Equipment industry which returned -5% over the past year.
Return vs Market: P2OD34 underperformed the BR Market which returned 13.1% over the past year.
Price Volatility
| P2OD34 volatility | |
|---|---|
| P2OD34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.7% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: P2OD34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine P2OD34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,000 | Jim Hollingshead | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.
Insulet Corporation Fundamentals Summary
| P2OD34 fundamental statistics | |
|---|---|
| Market cap | R$60.18b |
| Earnings (TTM) | R$1.07b |
| Revenue (TTM) | R$8.77b |
55.8x
P/E Ratio6.8x
P/S RatioIs P2OD34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P2OD34 income statement (TTM) | |
|---|---|
| Revenue | US$1.70b |
| Cost of Revenue | US$548.70m |
| Gross Profit | US$1.15b |
| Other Expenses | US$942.10m |
| Earnings | US$206.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 2.95 |
| Gross Margin | 67.67% |
| Net Profit Margin | 12.16% |
| Debt/Equity Ratio | 193.2% |
How did P2OD34 perform over the long term?
See historical performance and comparison